Impact of delayed diagnosis and treatment in clinically isolated syndrome and multiple sclerosis

Journal of Neuroscience Nursing

Volumn 45, Issue 6 SUPPL. 1, 2013, Pages

  Kennedy, Patricia M ^a  

^a RNCNP MSCN ^*  (United States)

Author keywords

Clinically isolated syndrome; Disease modifying treatment; Early treatment; Multiple sclerosis

Indexed keywords

BETA INTERFERON; GLATIRAMER; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT; PEPTIDE;

ARTICLE; DEMYELINATING DISEASE; HUMAN; METHODOLOGY; MULTIPLE SCLEROSIS; NURSING; NURSING DISCIPLINE; RISK FACTOR;

DEMYELINATING DISEASES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES; RISK FACTORS; SPECIALTIES, NURSING;

EID: 84892744969     PISSN: 08880395     EISSN: 19452810     Source Type: Journal    
DOI: 10.1097/JNN.0000000000000021     Document Type: Article

References (65)

1. Applebee, A., & Panitch, H. (2009). Early stage and long term treatment of multiple sclerosis with interferon-beta. Biologics, 3, 257-271.
2. Avonex. (2006). Avonex (Interferon beta-1a) IM Injection [package insert]. Cambridge, MA: Biogen Idec.
3. Betaseron. (2008). Betaseron (Interferon beta-1b) for SC Injection [package insert]. Montville, NJ: Bayer HealthCare Pharmaceuticals.
4. Calabresi, P. A. (2004). Diagnosis and management of multiple sclerosis. American Family Physician, 70, 1935-1944.
5. Carter, N. J., & Keating, G. M. (2010). Glatiramer acetate: A review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. Drugs, 70, 1545-1577.
6. Charil, A., & Filippi, M. (2007). Inflammatory demyelination and neurodegeneration in early multiple sclerosis. Journal of the Neurological Sciences, 259, 7-15.
7. Chiaravalloti, N. D., & DeLuca, J. (2008). Cognitive impairment in multiple sclerosis. Lancet Neurology, 7, 1139-1151.
8. Clerico, M., Faggiano, F., Palace, J., Rice, G., Tintore, M., & Durelli, L. (2008a). Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database of Systemic Reviews, (2), CD005278.
9. Clerico, M., Rivoiro, C., Contessa, G., Viglietti, D., & Durelli, L. (2008b). The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews. Clinical Neurology and Neurosurgery, 110, 878-885.
10. Comi, G. (2008). Clinically isolated syndrome: The rationale for early treatment. Nature Clinical Practice Neurology, 4, 234-235.
11. Comi, G., and De., S. N., Freedman, M. S., Barkhof, F., Polman, C. H., and Uitdehaag., B. M., I Kappos, L. (2012). Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): A phase 3 randomised controlled trial. Lancet Neurology, 11, 33-41.
12. Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernandez, O., I Hommes, O. R. (2001). Effect of early interferon treatment on conversion to definite multiple sclerosis: A randomised study. Lancet, 357, 1576-1582.
13. Comi, G., Martinelli, V., Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., I Filippi, M. (2009). Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet, 374, 1503-1511.
14. Compston, A., & Coles, A. (2002). Multiple sclerosis. Lancet, 359, 1221-1231.
15. Confavreux, C., Vukusic, S., Moreau, T., & Adeleine, P. (2000). Relapses and progression of disability in multiple sclerosis. New England Journal of Medicine, 343, 1430-1438.
16. Copaxone. (2007). Copaxone (glatiramer acetate injection) [package insert]. Kansas City, MO: TEVA Neuroscience.
17. Coyle, P. K. (2008). Early treatment of multiple sclerosis to prevent neurologic damage. Neurology, 71, S3-S7.
18. Di, F. M., and Anderson., V. M., Altmann, D. R., Swanton, J. K., and Plant., G. T., Thompson, A. J., & Miller, D. H. (2010). Brain atrophy and lesion load measures over 1 year relate to clinical status after 6 years in patients with clinically isolated syndromes. Journal of Neurology, Neurosurgery and Psychiatry, 81, 204-208.
19. Fernandez, O., Fernandez, V., Arbizu, T., Izquierdo, G., Bosca, I., Arroyo, R., Ide, R. E. (2010). Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study). Journal of Neurology, 257, 1500-1507.
20. Filippi, M., Rovaris, M., Inglese, M., Barkhof, F., and De., S. N., Smith, S., & Comi, G. (2004). Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet, 364, 1489-1496.
21. Galetta, S. L., & Markowitz, C. (2005). US FDA-approved disease-modifying treatments for multiple sclerosis: Review of adverse effect profiles. CNS Drugs, 19, 239-252.
22. Glanz, B. I., and Healy., B. C., Hviid, L. E., Chitnis, T., & Weiner, H. L. (2012). Cognitive deterioration in patients with early multiple sclerosis: A 5-year study. Journal of Neurology, Neurosurgery and Psychiatry, 83, 38-43.
23. Gold, R., and Wolinsky., J. S., Amato, M. P., & Comi, G. (2010). Evolving expectations around early management of multiple sclerosis. Therapeutic Advances in Neurological Disorders, 3, 351-367.
24. Goodin, D. S., & Bates, D. (2009). Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Multiple Sclerosis, 15, 1175-1182.
25. Goodin, D. S., Traboulsee, A., Knappertz, V., Reder, A. T., Li, D., Langdon, D., I Ebers, G. C. (2011). Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon beta-1b trial in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 83, 282-287.
26. Gout, O., Lebrun-Frenay, C., Labauge, P., Le Page, G. E., Clavelou, P., & Allouche, S. (2011). Prior suggestive symptoms in one-third of patients consulting for a "first," demye-linating event. Journal of Neurology, Neurosurgery and Psychiatry, 82, 323-325.
27. Hawker, K. (2011). Progressive multiple sclerosis: Characteristics and management. Neurologic Clinics, 29, 423-434.
28. Hurwitz, B. J. (2009). The diagnosis of multiple sclerosis and the clinical subtypes. Annals of Indian Academy of Neurology, 12, 226-230.
29. Jacobs, L. D., and Beck., R. W., Simon, J. H., Kinkel, R. P., and Brownscheidle., C. M., Murray, T. J., I Sandrock, A. W.; the CHAMPS Study Group (2000). Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. New England Journal of Medicine, 343, 898-904.
30. Kappos, L., and Freedman., M. S., Polman, C. H., Edan, G., Hartung, H. P., and Miller., D. H., I Sandbrink, R. (2007). Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet, 370, 389-397.
31. Kappos, L., and Freedman., M. S., Polman, C. H., Edan, G., Hartung, H. P., and Miller., D. H., I Pohl, C. (2009). Longterm effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurology, 8, 987-997.
32. Kappos, L., and Polman., C. H., Freedman, M. S., Edan, G., Hartung, H. P., and Miller., D. H., I Sandbrink, R. (2006). Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology, 67, 1242-1249.
33. Kelly, S. B., Chaila, E., Kinsella, K., Duggan, M., McGuigan, C., Tubridy, N., & Hutchinson, M. (2011). Multiple sclerosis, from referral to confirmed diagnosis: An audit of clinical practice. Multiple Sclerosis, 17, 1017-1021.
34. Kingwell, E., and Leung., A. L., Roger, E., Duquette, P., Rieckmann, P., & Tremlett, H. (2010). Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. Journal of the Neurological Sciences, 292, 57-62.
35. Kinkel, R. P., Dontchev, M., Kollman, C., Skaramagas, T. T., O'Connor, P. W., & Simon, J. H. (2011). Association between immediate initiation of intramuscular interferon beta-1a at the time of a clinically isolated syndrome and long-term outcomes: A 10-year follow-up of the controlled high-risk Avonex multiple sclerosis prevention study in ongoing neurological surveillance. Archives of Neurology, 69, 183-190.
36. Kinkel, R. P., Kollman, C., O'Connor, P., Murray, T. J., Simon, J., Arnold, D., I Wall, M.; CHAMPIONS study Group. (2006). IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology, 66, 678-684.
37. Lebrun, C., Bensa, C., Debouverie, M., de, S. J., Wiertlievski, S., Brochet, B., I Roullet, E. (2008). Unexpected multiple sclerosis: Follow-up of 30 patients with magnetic resonance imaging and clinical conversion profile. Journal of Neurology, Neurosurgery and Psychiatry, 79, 195-198.
38. Lim, S. Y., & Constantinescu, C. S. (2010). Current and future disease-modifying therapies in multiple sclerosis. International Journal of Clinical Practice, 64, 637-650.
39. Lukas, C., Minneboo, A., de Groot, V., Moraal, B., Knol, D. L., and Polman., C. H., I Vrenken, H. (2010). Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 81, 1351-1356.
40. Melo, A., Rodrigues, B., & Bar-Or, A. (2008). Beta interferons in clinically isolated syndromes: A meta-analysis. Arquivos de Neuro-Psiquiatria, 66, 8-10.
41. Miller, D., Barkhof, F., Montalban, X., Thompson, A., & Filippi, M. (2005). Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurology, 4, 281-288.
42. Motamed, M. R., Najimi, N., & Fereshtehnejad, S. M. (2007). The effect of interferon-beta1a on relapses and progression of disability in patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis. Clinical Neurology and Neurosurgery, 109, 344-349.
43. Mowry, E. M., Pesic, M., Grimes, B., Deen, S. R., Bacchetti, P., & Waubant, E. (2009). Clinical predictors of early second event in patients with clinically isolated syndrome. Journal of Neurology, 256, 1061-1066.
44. National Pharmaceutical Council Inc. (2005). Pain: Current understanding of assessment, management, and treatments. Retrieved from www.npcnow.org/ resources/PDFs/PainAddendum.pdf
45. O'Connor, P. (2003). The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: A post hoc analysis of data from CHAMPS. Clinical Therapeutics, 25, 2865-2874.
46. O'Connor, P., Kinkel, R. P., & Kremenchutzky, M. (2009). Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: Analysis of subgroups based on new risk criteria. Multiple Sclerosis, 15, 728-734.
47. Pakdaman, H., and Sahraian., M. A., Fallah, A., Pakdaman, R., Ghareghozli, K., Ghafarpour, M., I Shirani, A. (2007). Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event. Acta Neurologica Scandinavica, 115, 429-431.
48. Pelidou, S. H., Giannopoulos, S., Tzavidi, S., Lagos, G., & Kyritsis, A. P. (2008). Multiple sclerosis presented as clinically isolated syndrome: The need for early diagnosis and treatment. Therapeutics and Clinical Risk Management, 4, 627-630.
49. Polman, C., Kappos, L., Freedman, M. S., Edan, G., and Hartung., H. P., Miller, D. H., I Sandbrink, R. (2008). Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. Journal of Neurology, 255, 480-487.
50. Polman, C. H., and Reingold., S. C., Banwell, B., Clanet, M., Cohen, J. A., Filippi, M., I Wolinsky, J. S. (2011). Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Annals of Neurology, 69, 292-302.
51. Putzki, N., Fischer, J., Gottwald, K., Reifschneider, G., Ries, S., Siever, A., I Hartung, H. P. (2009). Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. European Journal of Neurology, 16, 713-720.
52. Rebif. (2008). Rebif (interferon beta-1a) sc injection [package insert]. Rockland, MA: EMD Serono.
53. Reuter, F., Zaaraoui, W., Crespy, L., Faivre, A., Rico, A., Malikova, I., I Audoin, B. (2011). Frequency of cognitive impairment dramatically increases during the first 5 years of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 82, 1157-1159.
54. Rieckmann, P. (2005). Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. International MS Journal, 12, 42-51.
55. Ross, A. P., & Thrower, B. W. (2010). Recent developments in the early diagnosis and management of multiple sclerosis. Journal of Neuroscience Nursing, 42, 342-353.
56. Salter, A. R., and Cutter., G. R., Tyry, T., Marrie, R. A., & Vollmer, T. (2010). Impact of loss of mobility on instrumental activities of daily living and socioeconomic status in patients with MS. Current Medical Research and Opinion, 26, 493-500.
57. Scalfari, A., Neuhaus, A., Degenhardt, A., Rice, G. P., and Muraro., P. A., Daumer, M., & Ebers, G. C. (2010). The natural history of multiple sclerosis: A geographically based study 10: Relapses and long-term disability. Brain, 133, 1914-1929.
58. Scott, T. F., & Schramke, C. J. (2010). Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later. Journal of the Neurological Sciences, 292, 52-56.
59. Sicotte, N. L. (2011). Magnetic resonance imaging in multiple sclerosis: The role of conventional imaging. Neurologic Clinics, 29, 343-356.
60. Summers, M., Swanton, J., Fernando, K., Dalton, C., and Miller., D. H., Cipolotti, L., & Ron, M. A. (2008). Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. Journal of Neurology, Neurosurgery and Psychiatry, 79, 955-958.
61. Thrower, B. W. (2007). Clinically isolated syndromes: Predicting and delaying multiple sclerosis. Neurology, 68, S12-S15.
62. Tintore, M., Rovira, A., Rio, J., Nos, C., Grive, E., Tellez, N., I Montalban, X. (2006). Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology, 67, 968-972.
63. Trojano, M., Pellegrini, F., Paolicelli, D., Fuiani, A., and Zimatore., G. B., Tortorella, C., I Amato, M. P.; Italian Multiple Sclerosis Database Network (MSDN) Group. (2009). Reallife impact of early interferon beta therapy in relapsing multiple sclerosis. Annals of Neurology, 66, 513-520.
64. Webb, U. H. (2008). Early interferon beta treatment in multiple sclerosis: Nursing care implications of the BENEFIT study. Journal of Neuroscience Nursing, 40, 356-361.
65. Weber, M. S., Menge, T., Lehmann-Horn, K., Kronsbein, H. C., Zettl, U., Sellner, J., I Stuve, O. (2012). Current treatment strategies for multiple sclerosisVEfficacy versus neurological adverse effects. Current Pharmaceutical Design, 18, 209-219.